Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
357 stopped studies mapped to Malignant Glioma and descendants · 90% state a reason
Over the 357 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06325683 | Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care… | Phase 2 | suspended | Mar 22, 2024 | National Cancer Institute (NCI) | Scheduled Interim Monitoring | Other (stated, no rule matched) |
| NCT07708961 | Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype… | Phase 2 | suspended | Jul 16, 2026 | Mayo Clinic | Pending receipt of study drug from sponsor | Other (stated, no rule matched) |
| NCT06129760 | Glioblastoma Remote Monitoring and Care - Research Protocol | N/A | suspended | Nov 13, 2023 | Case Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT06639607 | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and…(PRiME II) | Phase 1 / Phase 2 | suspended | Oct 15, 2024 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT06329570 | Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment… | Phase 1 / Phase 2 | suspended | Mar 26, 2024 | NaviFUS Corporation | FDA reviewing | Other (stated, no rule matched) |
| NCT03952598 | Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of… | Phase 2 | suspended | May 16, 2019 | National Cancer Institute (NCI) | Study on hold pending possible updates with the team. | Other (stated, no rule matched) |
| NCT03170141 | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | Phase 1 | terminated | May 30, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05607407 | Methimazole in Patients With Progressive Glioblastoma | Phase 2 | suspended | Nov 7, 2022 | Case Comprehensive Cancer Center | On hold per study team | Other (stated, no rule matched) |
| NCT03868943 | Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma(JAZZ) | Phase 2 | terminated | Mar 11, 2019 | Wake Forest University Health Sciences | Axsome has conducted a review of the ongoing IST program and are unable to continue supporting this… | Other (stated, no rule matched) |
| NCT05478837 | Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive…(PNOC018) | Phase 1 | terminated | Jul 28, 2022 | University of California, San Francisco | Logistical issues | Other (stated, no rule matched) |
| NCT06455189 | Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas | Phase 1 | withdrawn | Jun 12, 2024 | Case Comprehensive Cancer Center | Terminated IRB | Other (stated, no rule matched) |
| NCT06169280 | Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma | Phase 1 | suspended | Dec 13, 2023 | Northwestern University | Safety issues | Safety / toxicity |
| NCT05627323 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | Phase 1 | terminated | Nov 25, 2022 | Chimeric Therapeutics | IND application withdrawn | Other (stated, no rule matched) |
| NCT03866109 | A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT(TEM-GBM) | Phase 1 / Phase 2 | terminated | Mar 7, 2019 | Genenta Science | LVLP (pt GBM-01034) took place on 27may2026. The 2 remaining slots allocated by the protocol for… | Safety / toxicity |
| NCT05218408 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1…(CYNK001GBM02) | Phase 1 / Phase 2 | withdrawn | Feb 1, 2022 | Celularity Incorporated | No participants were enrolled. Study was withdrawn prior to treatment initiation. | Enrollment / accrual |
| NCT05695976 | GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM | — | suspended | Jan 25, 2023 | Duke University | The study is suspended while preplanned interim analysis is being completed. | Efficacy / futility |
| NCT06806228 | Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard… | Phase 1 | suspended | Feb 4, 2025 | Petrov, Andrey | The study protocol will be changed | Other (stated, no rule matched) |
| NCT01386710 | Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin… | Phase 1 / Phase 2 | suspended | Jul 1, 2011 | Northwell Health | PI left previous institution study will reopen at new institution. | Investigator |
| NCT03897491 | PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed… | Phase 2 | terminated | Apr 1, 2019 | photonamic GmbH & Co. KG | Low recruitment activities of clinical trial sites. | Enrollment / accrual |
| NCT04222309 | Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain… | Phase 1 | suspended | Jan 9, 2020 | Northwell Health | Per IRB closed and opened a new study. | Other (stated, no rule matched) |
| NCT05773326 | Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG | Early Phase 1 | terminated | Mar 17, 2023 | Nader Sanai | Study terminated due to unavailability of the investigational product required to continue the… | Other (stated, no rule matched) |
| NCT03382977 | Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine… | Phase 1 / Phase 2 | terminated | Dec 26, 2017 | VBI Vaccines Inc. | VBI Bankruptcy | Other (stated, no rule matched) |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual… | Phase 2 / Phase 3 | withdrawn | Sep 26, 2019 | NRG Oncology | NCI approval withdrawn | Other (stated, no rule matched) |
| NCT05557292 | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | Phase 1 | terminated | Sep 28, 2022 | Nicholas Butowski | Drug no longer provided by sponsor | Other (stated, no rule matched) |
| NCT05091866 | Natural Progesterone for the Treatment of Recurrent Glioblastoma | Early Phase 1 | terminated | Oct 25, 2021 | Emory University | Review of Drug Supply | Drug supply |
| NCT07553520 | Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients | N/A | withdrawn | Apr 28, 2026 | UNC Lineberger Comprehensive Cancer Center | Not stated | Other (stated, no rule matched) |
| NCT05513859 | Investigational Imaging Technique During Brain Surgery | N/A | suspended | Aug 24, 2022 | Emory University | Temporarily Closed | Other (stated, no rule matched) |
| NCT03334305 | Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas(ACTION) | Phase 1 | terminated | Nov 7, 2017 | University of Florida | due to lack of accrual/feasibility to complete accrual due to competing trials | Enrollment / accrual |
| NCT05934630 | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young… | — | terminated | Jul 7, 2023 | Pediatric Brain Tumor Consortium | The NCI will not extend the PBTC grant beyond March 31, 2026. | Other (stated, no rule matched) |
| NCT01507506 | Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With…(SPECTRO GLIO) | Phase 3 | terminated | Jan 11, 2012 | Institut Claudius Regaud | not stated | Not stated |
| NCT05753007 | A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma… | Phase 2 | terminated | Mar 3, 2023 | Mclean Hospital | Study terminated by sponsor due to low enrollment. | Enrollment / accrual |
| NCT02942264 | Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized… | Phase 1 / Phase 2 | terminated | Oct 24, 2016 | National Cancer Institute (NCI) | Unable to supply investigational agent, Zotiraciclib (TG02). | Drug supply |
| NCT04482933 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | Phase 2 | withdrawn | Jul 23, 2020 | Pediatric Brain Tumor Consortium | The PBTC lost federal funding and will cease operations in March 2026.PBTC-061 was permanently… | Enrollment / accrual |
| NCT04825275 | Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0… | Early Phase 1 | terminated | Apr 1, 2021 | Milton S. Hershey Medical Center | The study was stopped due to slow accrual. | Enrollment / accrual |
| NCT06193174 | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) | Phase 1 | terminated | Jan 5, 2024 | University of Alabama at Birmingham | Not enough eligible participants to enroll. | Enrollment / accrual |
| NCT04869449 | Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas | Early Phase 1 | terminated | May 3, 2021 | Milton S. Hershey Medical Center | Enrollment was stopped due to direction from the scientific review committee of the Penn State… | Enrollment / accrual |
| NCT05267106 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously…(FIGHT-209) | Phase 2 | terminated | Mar 4, 2022 | Incyte Corporation | Recruitment ceased after a pre-planned futility interim analysis indicated a low probability to… | Safety / toxicity |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | Phase 1 | terminated | Aug 4, 2023 | Novartis Pharmaceuticals | The decision was not based on any safety concerns | Safety / toxicity |
| NCT06359379 | Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With… | Phase 2 | terminated | Apr 11, 2024 | Shuttle Pharmaceuticals, Inc. | Terminated due to the sponsor's decision. | Sponsor / business decision |
| NCT03107780 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain… | Phase 1 | terminated | Apr 11, 2017 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT04657146 | Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma(LAMB-G) | — | suspended | Dec 8, 2020 | Duke University | Study undergoing amendment and funding changes. | Funding |
| NCT04209790 | Neoadjuvant Chemoradiation for Resectable Glioblastoma(NeoGlio) | Phase 2 | terminated | Dec 24, 2019 | Geisinger Clinic | Suspended to identify a permanent PI at site level. Decision to Terminate was made on 7/29/25… | Other (stated, no rule matched) |
| NCT03396575 | Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy…(BRAVO) | Phase 1 | terminated | Jan 11, 2018 | University of Florida | Not feasible to accrue due to competing studies | Enrollment / accrual |
| NCT06855628 | Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic… | Phase 2 | suspended | Mar 4, 2025 | Stanford University | low accrual | Enrollment / accrual |
| NCT04424966 | Infigratinib in Recurrent High-Grade Glioma Patients | Early Phase 1 | terminated | Jun 11, 2020 | Nader Sanai | Study drug no longer available. | Other (stated, no rule matched) |
| NCT05341947 | Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With… | Phase 1 | withdrawn | Apr 22, 2022 | Jeremy Rudnick, M.D | Lack of Funding | Funding |
| NCT04982926 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | Phase 1 | terminated | Jul 29, 2021 | Taiho Oncology, Inc. | After careful review of Taiho's ongoing portfolio and data obtained so far in the context of… | Safety / toxicity |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3… | Early Phase 1 | terminated | Jan 15, 2021 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT02742883 | A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) | Phase 2 | suspended | Apr 19, 2016 | Burzynski Research Institute | Clinical Hold | Other (stated, no rule matched) |
| NCT01849952 | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas | — | terminated | May 9, 2013 | Dartmouth-Hitchcock Medical Center | Study was administratively closed by IRB | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 15 hours agoSource updated Sep 29, 2026source: clinicaltrials